Domain Associates
Domain Associates is a venture capital firm with an exclusive focus on life sciences.
Business Model:
Revenue: $8.2M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Domain Associates Information
Geographic Data
Address: 1 Palmer Sq E
City: Princeton
State: NJ
Zip: 08542
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$164M
Social
Twitter
Linkedin
Crunchbase
Metrics
4,061,660Website Global Rank
2,913Website Monthly Traffic
Twitter Followers
Description
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA. Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.
Contact Phone:
+16096835656
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2014 | Zyga Technology | Series D | 2M |
| 5/2012 | Zyga Technology | Series C | 25M |
| 7/2017 | Sebacia | Series D | 0 |
| 10/2006 | Achaogen | Series B | 26M |
| 2/2013 | Glaukos | Series F | 30M |
| 1/2004 | Novacea | Series C | 35M |
| 11/2002 | Novacea | Series B | 36M |
| 4/2015 | Twelve | Series C | 35M |
| 2/2011 | Glaukos | Series E | 0 |
| 4/2011 | Benvenue Medical | Series C | 35.5M |
| 8/2002 | Proxima Therapeutics | Series E | 14M |
| 2/2001 | Proxima Therapeutics | Series D | 17M |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 12/2001 | TargetRx | Series C | 0 |
| 8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
| 11/2005 | Alimera Sciences | Series B | 31.8M |
| 1/2008 | Sonexa Therapeutics | Series A | 0 |
| 6/2004 | Somaxon Pharmaceuticals | Series B | 23M |
| 10/2009 | Zogenix | Series B | 36M |
| 3/2008 | Alimera Sciences | Series C | 30M |
| 11/2019 | Truvian Sciences | Series B | 27.1M |
| 11/2004 | Corthera | Series B | 15M |
| 3/2000 | iScribe | Series B | 21M |
| 10/1999 | Align Technology | Venture Round | 0 |
| 6/2010 | Veracyte | Series B | 28M |
| 5/2000 | Beansprout.net | Series C | 21.3M |
| 7/2020 | Exalys Therapeutics | Series A | 15M |
| 2/2007 | Carticept Medical | Series A | - |
| 12/2007 | REVA Medical | Venture Round | 42M |
| 3/2016 | Bionano Genomics | Series D | 9.9M |
| 4/2007 | ReVision Optics | Series D | 25M |
| 10/2004 | Vanda Pharmaceuticals | Series B | 18.5M |
| 12/1987 | Viagene | Seed Round | 1M |
| 3/2007 | Orqis Medical | Series D | 12M |
| 2/2008 | Obalon Therapeutics | Series A | 4.7M |
| 11/2016 | Gene Sciences, Inc. | Series A | 8M |
| 3/2010 | Carticept Medical | Series B | 20M |
| 8/2007 | Tobira Therapeutics | Series A | 31M |
| 7/2005 | Immune Control | Series A | 0 |
| 1/2016 | Singular Genomics | Seed Round | - |
| 9/2002 | Glaukos | Series A | 10M |
| 4/2005 | NovaCardia | Series A | - |
| 9/2006 | NovaCardia | Series B | 48M |
| 10/2012 | Cotera | Venture Round | 5M |
| 4/2013 | ReVision Optics | Equity | 15M |
| 6/2007 | Evoke Pharma | Series A | 3.3M |
| 11/2013 | Rightcare Solutions | Series B | 5M |
| 5/2010 | Sequent Medical | Series B | 15.6M |
| 10/2005 | Marinus Pharmaceuticals | Series A | 29.4M |
| 8/2020 | Fractyl Health | Series E | 0 |
| 1/2013 | Marinus Pharmaceuticals | Series C | 21M |
| 10/2018 | Milestone Pharmaceuticals | Series D | 80M |
| 11/2002 | Altea Therapeutics | Series B | 17M |
| 4/2008 | Nuon Therapeutics | Series B | 27M |
| 3/2005 | GenVault | Series A | 22.8M |
| 6/2003 | GI Dynamics | Series A | 4.1M |
| 11/2017 | Fractyl Health | Series D | 0 |
| 2/1999 | Pointshare | Series B | 7.3M |
| 9/2016 | Rox Medical | Series E | 40M |
| 4/2003 | Ansata Therapeutics | Series B | 2.5M |
| 10/2000 | IntraLase | Venture Round | 22M |
| 6/2012 | Benvenue Medical | Series D | 25M |
| 6/2014 | Benvenue Medical | Series E | 40M |
| 8/1991 | Genta | Venture Round | 8.4M |
| 10/2007 | Optherion | Series A | 37M |
| 5/2016 | Obalon Therapeutics | Series E | 0 |
| 4/2007 | DiObex | Series B | 24M |
| 4/2003 | ESP Pharma | Series B | 20M |
| 12/2016 | Axial Biotherapeutics | Series A | 19.1M |
| 2/2005 | Five Prime Therapeutics | Series C | 45M |
| 8/2010 | Achillion Pharmaceuticals | Post-IPO Equity | 50.1M |
| 10/2010 | ProteinSimple | Series F | 20M |
| 4/2017 | Epic Sciences | Series D | 0 |
| 1/2007 | Esprit Pharma | Series B | 25M |
| 12/2009 | Apnex Medical | Series B | 14M |
| 7/2010 | Zogenix | Venture Round | 0 |
| 9/2012 | Tandem Diabetes Care | Series D | 36.4M |
| 7/2004 | Alimera Sciences | Series A | 26.8M |
| 1/2017 | Adynxx | Series B | 16M |
| 2/2003 | Neose Technologies, Inc | Venture Round | 17M |
| 10/2012 | Rightcare Solutions | Series A | 1.8M |
| 2/2012 | Applied Proteomics | Series B | 22.5M |
| 7/2012 | Adynxx | Venture Round | 2M |
| 9/2018 | Epic Sciences | Series E | 0 |
| 8/2022 | Fractyl Health | Series F | - |
| 1/1991 | VIVUS | Seed Round | - |
| 11/2016 | Axial Biotherapeutics | Series A | 19.5M |
| 3/2003 | GenVault | Series A | 10M |
| 11/2006 | Aesthetic Sciences | Series A | 6M |
| 8/2003 | GenVault | Series A | 13M |
| 7/2008 | Tandem Diabetes Care | Series B | 13M |
| 4/2014 | Smart Medical Systems | Venture Round | 6.5M |
| 12/2003 | Novalar Pharmaceuticals | Series B | 5M |
| 12/2002 | SkinMedica | Series B | 9M |
| 1/2010 | Tandem Diabetes Care | Series C | 53M |
| 5/2001 | SenoRx | Venture Round | 19M |
| 11/2014 | Bionano Genomics | Series C | 0 |
| 10/2013 | Bionano Genomics | Series C | 0 |
| 6/2005 | Verus Pharmaceuticals | Series A | 0 |
| 3/2007 | Adastra Pharmaceuticals | Series A | 40M |
| 3/2010 | Nuon Therapeutics | Venture Round | 6M |
| 6/2012 | Twelve | Series B | 15M |
| 2/2011 | IntegenX | Series B | 0 |
| 7/2014 | Epic Sciences | Series C | 0 |
| 8/2010 | Nuon Therapeutics | Venture Round | 10M |
| 6/2015 | Celtaxsys | Series D | 0 |
| 1/2018 | Celtaxsys | Series E | - |
| 5/2009 | Neothetics | Series A | - |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 1/2010 | Twelve | Series A | 3M |
| 9/2015 | Kona Medical | Debt Financing | 10M |
| 12/2012 | Kona Medical | Series C | 10M |
| 7/2008 | NovaDigm Therapeutics | Series A | 4.1M |
| 9/2005 | DiObex | Series A | 7.1M |
| 1/2015 | CoLucid Pharmaceuticals | Series C | 0 |
| 2/2010 | Altair Therapeutics | Series B | 17M |
| 1/2006 | CoLucid Pharmaceuticals | Series A | 0 |
| 5/2002 | eNeura Therapeutics | Series A | 1M |
| 12/2009 | Afferent Pharmaceuticals | Series A | 23M |
| 8/2011 | CoLucid Pharmaceuticals | Venture Round | 0 |
| 7/2008 | CoLucid Pharmaceuticals | Series B | 0 |
| 9/2004 | Vascular Architects | Series E | 0 |
| 3/2007 | VentiRx Pharmaceuticals | Series A | 26.6M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 8/2004 | 3F Therapeutics | Series B | 14.2M |
| 6/2003 | Eunoe | Venture Round | 40M |
| 8/2007 | Helixis | Series A | 10M |
| 11/2004 | Ascenta Therapeutics | Series B | 30M |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 5/2005 | Celator Pharmaceuticals | Series B | 20M |
| 9/2010 | Tobira Therapeutics | Series B | 31M |
| 8/2017 | Milestone Pharmaceuticals | Series C | 55M |
| 6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
| 8/2016 | Bionano Genomics | Series D | 31.7M |
| 10/2004 | GeneOhm Sciences | Series C | 12M |
| 12/2009 | Regado Biosciences | Series D | 0 |
| 2/2008 | Ocera Therapeutics | Series C | 0 |
| 7/2014 | Xagenic | Series B | 0 |
| 7/2015 | Xagenic | Series B | 11.8M |
| 5/2008 | Esperion | Series A | 22.8M |
| 11/2015 | Fractyl Health | Series C | 57M |
| 2/2008 | BioVascular | Series C | 10.9M |
| 3/2012 | Sequent Medical | Series C | 26M |
| 9/2003 | NovaCardia | Venture Round | 22M |
| 1/2012 | Carticept Medical | Series C | 10M |
| 4/2011 | Ocunexus Therapeutics | Series B | 0 |
| 3/2011 | Astute Medical | Series B | 13M |
| 3/2003 | TargetRx | Series C | 0 |
| 1/2003 | Iomai Corporation | Series C | 54M |
| 7/2006 | ROX Medical | Series B | 10.1M |
| 7/2012 | Obalon Therapeutics | Series C | 16.5M |
| 8/2008 | Neuron Systems | Series A | 9M |
| 6/2008 | ROX Medical | Series C | 33M |
| 9/2014 | Colorescience | Series B | 15M |
| 10/2013 | NovaDigm Therapeutics | Series B | 7M |
| 5/2010 | Astute Medical | Series B | 26.5M |
| 11/1999 | Medpool | Venture Round | 12M |
| 1/2004 | Orexigen Therapeutics | Series A | 11M |
| 7/2020 | Nobias Therapeutics | Series A | 0 |
| 5/2020 | Seraphina Therapeutics | Series A | 0 |
| 1/2014 | Atara Biotherapeutics | Series B | 13.5M |
| 6/2015 | Milestone Pharmaceuticals | Series B | 0 |
| 1/2001 | Volcano Corporation | Venture Round | - |
| 3/2005 | Novalar Pharmaceuticals | Series C | 27M |
| 5/2003 | Santarus | Series D | 51.4M |
| 7/2013 | aTyr Pharma | Series D | 49M |
| 12/2007 | Corthera | Series C | 23M |
| 9/2014 | VentiRx Pharmaceuticals | Series B | 50.6M |
| 1/2015 | Sera Prognostics | Series B | 20M |
| 11/2014 | Sera Prognostics | Series B | 5M |
| 7/2018 | Omniome | Series B | 0 |
| 10/2003 | OmniSonics Medical Technologies | Series C | 43M |
| 3/2007 | Regado Biosciences | Series C | 23M |
| 1/2016 | Benvenue Medical | Equity | 23M |
| 1/2003 | Vascular Architects | Series D | 0 |
| 1/2010 | The Foundry | Series A | 3M |
| 10/2021 | Axial Biotherapeutics | Series C | 0 |
| 6/1999 | Cardiodynamics International | Venture Round | 5M |
| 11/2009 | IntegenX | Series B | 18.1M |
| 6/2013 | Veracyte | Series C | 28M |
| 6/2008 | Meritage Pharma | Series A | 22.5M |
| 4/2010 | Achaogen | Series C | 56M |
| 11/2012 | Epic Sciences | Series B | 13M |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 3/2013 | Atara Biotherapeutics | Venture Round | 1M |
| 3/2000 | SelfCare.com | Venture Round | 0 |
| 7/2012 | Bionano Genomics | Series B | 0 |
| 9/2010 | Eddingpharm (Cayman) | Series B | 24M |
| 5/2002 | Onyx Pharmaceuticals | Venture Round | 20M |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 1/2004 | Peninsula Pharmaceuticals | Series C | 0 |
| 9/2000 | Medpool | Venture Round | 10M |
| 9/2013 | Otonomy | Series C | 45.9M |
| 1/2006 | ProteinSimple | Series B | 0 |
| 12/2000 | Molecular Staging | Series D | 41.3M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 6/2016 | Miramar Labs | Venture Round | - |
| 6/2015 | Sebacia | Series C | 12M |
| 4/2014 | Sequent Medical | Series D | 20M |
| 9/2007 | Sequel Pharmaceuticals | Series A | 20M |
| 4/2007 | NovaCardia | Series B | 18M |
| 11/2007 | Novalar Pharmaceuticals | Series D | 30M |
| 9/2000 | Senomyx | Series B | 10M |
| 12/2012 | Neothetics | Series C | 20.6M |
| 3/2001 | Santarus | Series C | 33.2M |
| 2/2014 | Neothetics | Series C | 8M |
| 12/2011 | IntegenX | Series C | 40M |
| 1/2012 | Ariosa Diagnostics | Series C | 52.7M |
| 8/2008 | Glaukos | Series D | 35M |
| 3/2011 | Bionano Genomics | Series B | 0 |
| 6/2018 | WindMIL Therapeutics | Series B | 0 |
| 9/2006 | Cantex Pharmaceuticals | Series B | 19M |
| 6/2003 | Orqis Medical | Series C | 25M |
| 4/2001 | iScribe | Series D | 15M |
| 8/2006 | Esprit Pharma | Series B | 90.8M |
| 11/2011 | Sera Prognostics | Series A | 19.3M |
| 1/2004 | Auxeris Therapeutics | Series A | 1.6M |
| 5/2007 | Apnex Medical | Series A | 16.1M |
| 10/2006 | Ocunexus Therapeutics | Series A | 20M |
| 12/2001 | Aradigm | Convertible Note | 48.4M |
| 4/2010 | Adastra Pharmaceuticals | Venture Round | 0 |
| 4/2004 | Imagine Pharmaceuticals | Series A | 3.7M |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 3/2017 | Dicerna Pharmaceuticals | Post-IPO Debt | 0 |
| 8/2006 | Zogenix | Series A | 60M |
| 1/2008 | Zogenix | Series B | 18M |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 10/2013 | NovaDigm Therapeutics | Venture Round | 7M |
| 7/2012 | Ocunexus Therapeutics | Series B | 0 |
| 7/2013 | ReVision Optics | Series E | 55M |
| 10/2014 | Miramar Labs | Series D | 26M |
| 12/2012 | Evofem Biosciences | Series C | 20.6M |
| 9/2012 | Rox Medical | Series D | 6M |
| 7/2008 | Celator Pharmaceuticals | Series C | 22.5M |
| 2/2014 | Evofem Biosciences | Series C | 8M |
| 10/2002 | Peninsula Pharmaceuticals | Series B | 0 |
| 4/2005 | 3F Therapeutics | Series C | 6M |
| 8/2007 | Celator Pharmaceuticals | Series C | 10M |
| 5/1992 | NPS Pharmaceuticals | Seed Round | 5M |
| 9/2010 | Celator Pharmaceuticals | Series D | 0 |
| 10/2005 | eNeura Therapeutics | Series B | 5.1M |
| 9/2014 | Fractyl Health | Series B | 19.8M |
| 12/1998 | OraPharma Inc. (acquired by JNJ) | Venture Round | 16M |
| 12/2005 | Celladon | Series B | 30M |
| 9/2003 | Conforma Therapeutics | Series C | 30M |
| 4/2009 | ProteinSimple | Series C | 10M |
| 1/2015 | Obalon Therapeutics | Series D | 0 |
| 1/2009 | BiPar Sciences | Series C | 20M |
| 2/2007 | BiPar Sciences | Series B | 35M |
| 4/2007 | Ascenta Therapeutics | Series C | 50M |
| 7/2006 | Ocera Therapeutics | Series B | 12M |
| 1/2010 | VentiRx Pharmaceuticals | Series A | 25M |
| 10/2012 | Veracyte | Private Equity Round | 14.9M |
| 12/2013 | Atara Biotherapeutics | Series B | 38.5M |
| 7/2003 | Corthera | Series A | 2.1M |
| 5/2009 | Marinus Pharmaceuticals | Series B | 20M |
| 8/2011 | NeuroPace | Venture Round | 0 |
| 5/2004 | NuVasive | Venture Round | 9.8M |
| 3/2015 | aTyr Pharma | Series E | 76M |
| 4/2013 | Esperion | Venture Round | 33M |
| 8/2013 | Applied Proteomics | Series C | 28M |
| 5/2007 | Asmacure Ltée | Series A | 9M |
| 6/2008 | GenVault | Series B | 13M |
| 4/2017 | ChromaCode | Series B | 12M |
| 4/2013 | Afferent Pharmaceuticals | Series B | 5M |
| 12/2019 | ChromaCode | Series C | 0 |
| 1/2020 | Omniome | Series C | 60M |
| 9/1993 | GelTex Pharmaceuticals | Venture Round | 6.8M |
| 4/2005 | TargetRx | Series D | 0 |
| 9/2007 | Novalar Pharmaceuticals | Series D | 30M |
| 1/2005 | NeuroPace | Venture Round | 30M |
| 4/2001 | Xcel Pharmaceuticals | Venture Round | 70M |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 7/2009 | Oraya Therapeutics | Series C | 42M |
| 5/2012 | Kona Medical | Series C | 0 |
| 4/2005 | Orexigen Therapeutics | Series B | 35M |
| 7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
| 7/2010 | ReVision Optics | Series D | 35M |
| 12/2012 | Regado Biosciences | Series E | 0 |
| 11/2016 | ReVision Optics | Venture Round | 32M |
| 7/2013 | Dicerna Pharmaceuticals | Series C | 0 |
| 4/2007 | GenVault | Venture Round | 18M |
| 12/2001 | Pharmion | Venture Round | 65M |
| 11/2018 | Antios Therapeutics | Series A | 0 |
| 8/2010 | Otonomy | Series B | 38.5M |
| 1/2005 | GeneOhm Sciences | Series C | 0 |
| 6/2000 | TargetRx | Series B | 12M |
| 6/2000 | Align Technology | Series D | 105M |
| 4/2005 | Receptor Biologix | Series A | 33.6M |
| 10/2010 | aTyr Pharma | Series C | 23M |
| 9/2005 | Esprit Pharma | Series A | 103.7M |
| 6/2012 | Astute Medical | Series C | 40.4M |
| 4/2007 | Syndax Pharmaceuticals | Series A | 40M |
| 3/2010 | Syndax Pharmaceuticals | Series A | 9M |
| 8/2013 | Syndax Pharmaceuticals | Series B | 0 |
| 10/2009 | Alimera Sciences | Series C | 5M |
| 2/2012 | Apnex Medical | Series C | 20M |
| 3/2009 | GI Dynamics | Series C | 0 |
| 2/2019 | Axial Biotherapeutics | Series B | 25M |
| 6/2010 | Corridor Pharmaceuticals | Series A | 0 |
| 4/2014 | Otonomy | Series D | 49M |
| 7/2004 | SkinMedica | Series D | 30M |
| 4/2005 | SkinMedica | Series E | 0 |
| 4/2006 | SkinMedica | Series E | 0 |
| 5/2004 | GI Dynamics | Series B | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 10/2021 | Axial Biotherapeutics | Series C | 0 |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 8/2020 | Fractyl Health | Series E | 0 |
| 7/2020 | Nobias Therapeutics | Series A | 0 |
| 7/2020 | Exalys Therapeutics | Series A | 0 |
| 5/2020 | Seraphina Therapeutics | Series A | 0 |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 1/2020 | Omniome | Series C | 0 |
| 12/2019 | ChromaCode | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
